NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
NurExone Biologic Inc. (NRXBF) presented promising preclinical data on optic nerve regeneration at the ARVO 2025 conference in Salt Lake City. The study, led by Prof. Ygal Rotenstreich, demonstrated that ExoPTEN successfully restored retinal activity and improved optic nerve structure in rat models with optic nerve compression.
The company is advancing its ExoTherapy™ platform, which includes programs for spinal cord and facial nerve regeneration. Previous preclinical spinal cord studies showed ExoPTEN restored motor function in 75% of animals following complete transection. The company is now proceeding to study the therapy in a glaucoma model, targeting a condition that causes significant economic burden to healthcare systems.
NurExone Biologic Inc. (NRXBF) ha presentato dati preclinici promettenti sulla rigenerazione del nervo ottico alla conferenza ARVO 2025 a Salt Lake City. Lo studio, guidato dal Prof. Ygal Rotenstreich, ha dimostrato che ExoPTEN ha ripristinato con successo l'attività retinica e migliorato la struttura del nervo ottico in modelli di ratto con compressione del nervo ottico.
L'azienda sta sviluppando la sua piattaforma ExoTherapy™, che include programmi per la rigenerazione del midollo spinale e del nervo facciale. Studi preclinici precedenti sul midollo spinale hanno mostrato che ExoPTEN ha ripristinato la funzione motoria nel 75% degli animali dopo una completa tranciatura. Ora l'azienda sta proseguendo con lo studio della terapia in un modello di glaucoma, una condizione che comporta un significativo onere economico per i sistemi sanitari.
NurExone Biologic Inc. (NRXBF) presentó datos preclínicos prometedores sobre la regeneración del nervio óptico en la conferencia ARVO 2025 en Salt Lake City. El estudio, dirigido por el Prof. Ygal Rotenstreich, demostró que ExoPTEN restauró con éxito la actividad retiniana y mejoró la estructura del nervio óptico en modelos de rata con compresión del nervio óptico.
La compañía está avanzando con su plataforma ExoTherapy™, que incluye programas para la regeneración de la médula espinal y del nervio facial. Estudios preclínicos previos en médula espinal mostraron que ExoPTEN restauró la función motora en el 75% de los animales tras una transección completa. Ahora la empresa continúa estudiando la terapia en un modelo de glaucoma, una condición que representa una carga económica significativa para los sistemas de salud.
NurExone Biologic Inc. (NRXBF)는 솔트레이크시티에서 열린 ARVO 2025 학회에서 시신경 재생에 관한 유망한 전임상 데이터를 발표했습니다. Ygal Rotenstreich 교수 주도 하에 진행된 연구에서 ExoPTEN이 시신경 압박 모델 쥐에서 망막 활동을 성공적으로 회복시키고 시신경 구조를 개선한 것으로 나타났습니다.
회사는 척수 및 안면 신경 재생 프로그램을 포함하는 ExoTherapy™ 플랫폼을 발전시키고 있습니다. 이전 척수 전임상 연구에서는 ExoPTEN이 완전 절단 후 75%의 동물에서 운동 기능을 회복시켰습니다. 현재는 이 치료법을 녹내장 모델에 적용해 연구를 진행 중이며, 이는 의료 시스템에 상당한 경제적 부담을 주는 질환을 목표로 하고 있습니다.
NurExone Biologic Inc. (NRXBF) a présenté des données précliniques prometteuses sur la régénération du nerf optique lors de la conférence ARVO 2025 à Salt Lake City. L'étude, dirigée par le Prof. Ygal Rotenstreich, a démontré que ExoPTEN a réussi à restaurer l'activité rétinienne et à améliorer la structure du nerf optique chez des modèles de rats souffrant de compression du nerf optique.
L'entreprise fait progresser sa plateforme ExoTherapy™, qui comprend des programmes pour la régénération de la moelle épinière et du nerf facial. Des études précliniques antérieures sur la moelle épinière ont montré qu’ExoPTEN a restauré la fonction motrice chez 75% des animaux après une section complète. L’entreprise poursuit désormais l’étude de cette thérapie dans un modèle de glaucome, une pathologie représentant un fardeau économique important pour les systèmes de santé.
NurExone Biologic Inc. (NRXBF) präsentierte vielversprechende präklinische Daten zur Regeneration des Sehnervs auf der ARVO 2025-Konferenz in Salt Lake City. Die Studie unter Leitung von Prof. Ygal Rotenstreich zeigte, dass ExoPTEN die Netzhautaktivität erfolgreich wiederherstellte und die Struktur des Sehnervs bei Rattenmodellen mit Sehnervkompression verbesserte.
Das Unternehmen entwickelt seine ExoTherapy™-Plattform weiter, die Programme zur Regeneration des Rückenmarks und des Gesichtsnervs umfasst. Frühere präklinische Studien am Rückenmark zeigten, dass ExoPTEN die motorische Funktion bei 75% der Tiere nach kompletter Durchtrennung wiederherstellte. Das Unternehmen plant nun, die Therapie in einem Glaukommodell zu untersuchen, das eine erhebliche wirtschaftliche Belastung für Gesundheitssysteme darstellt.
- ExoPTEN demonstrated successful restoration of retinal activity and improved optic nerve structure in rat models
- Previous spinal cord studies showed 75% success rate in motor function restoration
- Platform technology shows potential for multiple applications (optic, spinal, facial nerve regeneration)
- Research presented at prestigious ARVO conference, indicating growing scientific recognition
- Still in preclinical stage with no human trials yet
- Results limited to controlled rat models, requiring further validation
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce that its preclinical data on optic nerve regeneration study was presented today at the Annual Meeting of the Association for Research in Vision and Ophthalmology (“ARVO) in Salt Lake City Utah, the world's largest and most respected vision science conference.
The data, presented by Prof. Ygal Rotenstreich, lead investigator and Director of the Retinal Research Lab at Sheba Medical Center, showed that ExoPTEN restored retinal activity and improved optic nerve structure in a controlled rat model of optic nerve compression. The study, initially announced in July and December 2024, has since been expanded to include a larger group of animals.
Prof. Ygal Rotenstreich commented “We’re proud to present this progress in optic nerve regeneration at ARVO, where the future of vision science is shaped”. He further noted “Our presentation generated a lot of interest from our peers and the scientific community who are anxiously awaiting real breakthroughs in this field.
Prof. Michael Belkin, founder of Tel Aviv University's Goldschleger Eye Research Institute where the study took place and a member of NurExone’s Scientific Advisory Board, noted “The results presented at ARVO show a distinct possibility that ExoPTEN can be used in treating optic nerve pathologies. We are proceeding to study an actual glaucoma model to examine the possibility of treating optic nerves which cause vision incapacitation from this common disease.”
Dr. Lior Shaltiel, CEO of NurExone also added “We’re seeing damaged neurons survive and regain function in models that were previously considered irreversible, challenging long-standing assumptions in neurodegeneration. Acute glaucoma carries a high risk of irreversible blindness and an associated economic burden that costs the healthcare system billions per year1. By preserving vision in even a fraction of these cases, a therapy, like ExoPTEN, could deliver clinical and economic value.”
The therapy for acute glaucoma is being developed as part of NurExone’s broader ExoTherapy™ platform, which also includes programs for spinal cord and facial nerve regeneration. In preclinical spinal cord studies, ExoPTEN restored motor function in
The ARVO Annual Meeting is the largest and most respected gathering in vision research, bringing together over 10,000 experts from academia, industry, and clinical practice. NurExone’s inclusion in the ARVO scientific program reflects growing recognition of exosome-based strategies as a potential new frontier in regenerative medicine.
About NurExone
NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets i. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations – U.S. and Canada
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company receiving all regulatory approvals; the Company advancing towards clinical and commercial breakthroughs in regenerative medicine; the Company enhancing its presence in key markets; the advancement of the Company’s therapeutic programs and clinical milestones; the results of the Company’s preclinical trials and its suggestion of a promising treatment pathway for spinal cord injury (“SCI”); the results of the Company’s preclinical trials and its suggestion of a promising treatment pathway for glaucoma; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN having the potential to address vision loss and improve patient lives; the Company is advancing toward clinical translation in several high-impact indications; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health.
These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company will realize on the benefits of exosome loaded drugs in regenerating or repairing damaged nerves; the ability of the Company’s products to be used for patient treatment; the Company will fulfill its intended future plans and expectations; there being growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; the Company will carry out its pre-clinical trials and realize upon the benefits of the pre-clinical trials; the Company having the ability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and cell therapy applications; the Company will receive all regulatory approvals; the Company will have clinical and commercial breakthroughs in regenerative medicine; the Company will be able to realize its future development plans, operational initiatives, and strategic objectives; the Company’s ability to advance its therapeutic programs and clinical milestones; the results of the Company’s preclinical trials and its ability to be a promising treatment pathway for SCI; the Company’s ability in advancing toward clinical translation in several high-impact indications; the results of the Company’s preclinical trials and its suggestion of a promising treatment pathway for glaucoma; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN having the ability to address vision loss and improve patient lives; the Company having the ability to advance toward clinical translation in several high-impact indications; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company’s products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the inability of the Company to collaborate with pharma companies; the Company’s inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company’s inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company’s inability to expand into further studies; the Company will not receive all required regulatory approvals; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the Company will be unable to enhance its presence in key markets; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; the Company will not realize its future development plans, operational initiatives, and strategic objectives; the Company will not advance its therapeutic programs and clinical milestones; the Company will not engage with regulatory agencies; the results of the Company’s preclinical trials not being a promising treatment pathway for SCI; the Company not advancing toward clinical translation in several high-impact indications; the Company not developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN not addressing vision loss or improving patient lives; the Company does not advance toward clinical translation in several high-impact indications; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
i Spinal cord injury , Glaucoma
______________________________________________________
1 https://preventblindness.org/wp-content/uploads/2020/04/Economic-Burden-of-Vision-Final-Report_130611_0.pdf
FAQ
What were the key findings of NurExone's (NRXBF) preclinical study presented at ARVO 2025?
How effective is NurExone's ExoPTEN in spinal cord injury treatment?
What conditions does NurExone's ExoTherapy platform target?
What is the current development stage of NurExone's (NRXBF) ExoPTEN therapy?
Where was NurExone's (NRXBF) preclinical data presented in May 2025?
